The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET permits a more sensitive assessment of metabolically active tumor, treatment failure, and distant non-contrast-enhancing progression in this patient with anaplastic oligodendroglioma, WHO grade III, where progression on MRI was challenged because of changing patterns of speckled new and dissolving old non-measurable contrast enhancement.
Original languageEnglish
Title of host publicationClinical Nuclear Medicine in Neurology : An Atlas of Challenging Cases
EditorsAndrea Varrone, Silvia Morbelli, Valentina Garibotto
Number of pages5
Place of PublicationCham
PublisherSpringer International Publishing
Publication date2022
ISBN (Print)978-3-030-83598-9
Publication statusPublished - 2022


Dive into the research topics of 'Case 24: Progressive Glioma'. Together they form a unique fingerprint.

Cite this